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Abstract
Heart failure syndrome is defined as the inability of the heart to deliver adequate blood 
to the body to meet end-organ metabolic needs and oxygenation at rest or during mild 
exercise. Myocardial dysfunction can be defined as systolic and/or diastolic, acute 
or chronic, compensated or uncompensated, or uni- or biventricular. Several counter-
regulatory mechanisms are activated depending on the duration of the heart failure. 
Neurohormonal reflexes such as sympathetic adrenergic system, renin-angiotensin cas-
cade, and renal and peripheral alterations attempt to restore both cardiac output and 
end-tissue perfusion. An adequate stroke volume cannot be ejected from the left ven-
tricle, which shifts the whole pressure-volume relationship to the right (systolic failure). 
Adequate filling cannot be realized due to diastolic stiffness, which shifts the diastolic 
pressure-volume curve upward without affecting the systolic pressure-volume curve 
(diastolic failure). Left ventricular heart failure is the dominant picture of heart failure 
syndrome, but the right heart can develop isolated failure as well. Biventricular failure 
is mostly an end-stage clinical situation of the heart failure syndrome. More recently, the 
rise in the incidence of right ventricular failure can be seen after the implantation of a left 
ventricular assist device. This chapter clarifies and presents pathophysiologic alterations 
in heart failure syndrome.
Keywords: heart failure, systolic dysfunction, diastolic dysfunction, myocardial 
stiffness, ventricular dilatation, neurohormonal, renin-angiotensin, norepinephrine
Heart failure is an epidemic contributing considerably to the overall cost of health care in 
developed and also developing countries. Heart failure syndrome (HFS) is the currently 
accepted term describing a systemic disease affecting several organs, creating high morbidity 
and mortality rates due to the heart’s inability to supply oxygenated blood, including metabo-
lites, to end organs and peripheral tissues (Table 1) [1]. Acute event or acute refractory form 
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of chronic heart failure can be fatal, whereas chronic prognosis is characterized by terminal 
congestive heart failure symptoms. The failing heart strives to balance “preload” and “after-
load” for compensation of impaired contractility and to deter the development of congestion 
using a myriad of mechanisms.
1. Left heart failure
Left heart failure (LHF), with any structural and/or functional cardiac abnormalities, is a complex 
clinical state characterized by left ventricular pump dysfunction and related clinical symptoms 
(dyspnea, fatigue, exercise intolerance, etc.), including signs of volume overload (pulmonary 
crackles, peripheral edema, etc.) [2]. All steps of energy extraction, transfer, and utilization are 
affected, with metabolic failure being the important underlying pathophysiologic mechanism 
causing first myocardial and then systemic decompensation [3]. The pathophysiologic state per-
petuates the progression of the failure, regardless of the precipitating event via several compen-
satory mechanisms. Compensatory mechanisms exist on every level of this scenario to restrain 
the clinical symptoms via correction of the global imbalance between the catabolic and anabolic 
status; however, they can lead to further myocardial deterioration and worsening HFS.
The most important classification of LHF is dependent on whether the left ventricular ejec-
tion fraction (LVEF) is reduced or preserved. The standard relationship between intracavitary 
volume and pressure values is affected in heart failure, and left ventricular pressure-volume 
curves change according to the failure type (Figure 1). In systolic LHF, an adequate stroke 
volume cannot be sustained due to reduced ventricular systolic contractile function, which 
shifts the whole pressure-volume relationships to the right. In diastolic LHF, an adequate fill-
ing cannot be realized due to diastolic stiffness (poor ventricular compliance, impaired relax-
ation, worsened end-diastolic pressure), which shifts the diastolic pressure-volume curve 
upward; however, the systolic pressure-volume curve does not change.
(1) Activated feedback signals from peripheral reflex circuit
 a. Inflammation
 b. Anabolic blunting (proteolysis)
 c. Insulin resistance (>50% reducing normal anabolic responses)
 d. Oxygen radical accumulation
(2) Global metabolic imbalance (increased catabolic/anabolic imbalance)
(3) Systemic dysregulation of several hormonal pathways
(4) Multi-organ dysfunction (hyperbilirubinemia, uremia, anemia, hypoalbuminemia, etc.)
(5) Development of sarcopenia and cachexia
Table 1. Heart failure syndrome as a multisystem disease.
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From asymptomatic to symptomatic stages, several counterregulatory mechanisms are acti-
vated (Table 2). First, inadequate stroke volume induces sympathetic nervous system acti-
vation, which increases cardiac contractile frequency and strength. This chronotropic effect 
leads to enhancement of total stroke volume per minute via increasing heart rate frequency, 
but this positive effect is reversed after tachycardia reaches a threshold of 140–150 beats/
min (Figure 2). The next step is the augmentation of intravascular volume via neurohor-
monal system activation, which results in increasing intravascular volume, enlarging ven-
tricular chambers, and improvement in myocardial fiber tension [4]. The inotropic effect via 
the Frank-Starling mechanism increases myocardial contraction power, but this positive 
effect reverses after the sarcomere length reaches the upper limit of 2.2 μm (Figure 3). At 
this stage, no physiologic mechanism can improve the contractility, stroke volume, and 
cardiac decompensation, and the left ventricle (LV) undergoes progressive alterations 
from  reversible cellular to irreversible myocardial remodeling. The heart is a self-renewing 
Figure 1. Left ventricular pressure-volume relationships: the green line represents the diastolic pressure-volume 
relationship, and the red line represents the end-systolic pressure-volume relationship. Both curves are shifted to the right 
in dilated CMP (blue arrow), to the left in hypertrophic CMP (green arrow), and only diastolic curve is shifted upward 
in restrictive CMP (red arrow). CMP, cardiomyopathy; LAP, left atrial pressure; LVEDP, left ventricular end-diastolic 
pressure; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESP, left ventricular 
end-systolic pressure; LVESV, left ventricular end-systolic volume; SAP, systolic aortic pressure; SV, stroke volume.
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organ, characterized by an increase in myocyte turnover rate during pathological stress, 
especially in heart failure. The turnover mechanism becomes overwhelmed by a faster loss 
of myocytes, and this unfavorable imbalance causes the progression of ventricular remodel-
ing during heart failure.
(a) Activation of neurohormonal systems
(b) Increasing preload to help to sustain cardiac performance
(c) Myocardial cell regeneration and apoptosis
(d) Myocardial hypertrophy and/or ventricular dilatation
(e) Compensation of symptoms
(f) Irreversible myocardial remodeling
(g) Decompensation of clinic status
(h) End-stage multi-organ dysfunction
Table 2. Step-by-step counterregulatory actions during ventricular failure.
Figure 2. Relationship between cardiac output and heart rate (chronotropy; Bowditch effect).
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1.1. Morphological changes
Any of the cardiac pathology causing myocardial dysfunction results in abnormal myocyte 
growth, with a resultant cascade of gene activation stimulating cardiac remodeling. The hall-
marks of cardiac remodeling are myocardial cell hypertrophy and cardiac dilatation with 
increased interstitial matrix formation. This compensatory mechanism to preserve contraction 
capability shifts to a maladaptive process after a cutoff level and contributes to the worsening 
of heart failure during myocardial degenerative progression. Progressive necrotic, apoptotic, 
or autophagic myocyte loss may contribute to worsening cardiac dysfunction and left ventric-
ular remodeling. Changes within the extracellular matrix such as fibrillary collagen synthesis 
and degradation, loss of collagen struts, and collagen cross-linking characterize subsequent 
myocardial adaptation during cardiac remodeling. Cardiac fibroblasts are transformed into 
myofibroblasts and migrate into the area surrounding injured tissues to secrete collagen and 
restrict the injured site by scar formation (myocardial fibrosis).
Extracellular matrix requires myocytes to take appropriate position during the cardiac cycles 
and allows the opening of capillary vessels. Cardiac mitochondria are the main structure to 
generate energy, in the form of adenosine triphosphate (ATP), through oxidative phosphory-
lation and to continue cardiac function. Therefore, mitochondrial dysfunction is the major 
determinant for the development of heart failure via activation of cell death caused by exces-
sive production of reactive oxygen radicals. In the early stage of left ventricular hypertrophy, 
the number of cardiac myocytes with preserved cellular organization increases; however, 
they are larger than normal due to the growing number of myofibrils and mitochondria, 
as well as the large size of the mitochondria and nuclei. Myocytes also increase autophagic 
Figure 3. Relation between cardiac output and left ventricular filling (inotropy; Frank-Starling effect).
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activity in order to maintain ATP levels, to sustain contractile function during these demand-
ing nutritional and energy-consuming phases. Mitophagy is a critical mitochondrial quality 
control mechanism in myocytes, whereas damaged mitochondria and autophagosomes are 
selectively sequestered and broken down. This process helps to prevent oxidative damage 
or myocardial stress under baseline conditions, whereas impaired or dysregulated mitoph-
agy is a major contributor to the development and progression of heart failure [5]. Inhibiting 
autophagy reduces ATP levels and exacerbates remodeling, whereas enhancing autophagy 
mitigates remodeling and cardiac dysfunction. The hemodynamic and neurohormonal altera-
tions cause an increase in cytosolic calcium entry, which augments myocardial contractility; 
on the other hand, it impairs the lusitropic effect and leads to increased myocardial energy 
consumption resulting in further reduction of cardiac function.
Long-standing hypertrophy disrupts cellular organization, such as enlarged nuclei with myo-
fibril displacement. Additionally, some collagen lytic enzymes (matrix metalloproteinase) acti-
vated by neurohormonal substances can create progressive degradation of extracellular matrix. 
In late stages, the pathologic progress is characterized by myocytolysis, a disruption of sarco-
meres and Z-bands. In the chronic phase, some components increase and cause myocyte death, 
creating perivascular fibrosis within intramuscular vessels. This process causes fibrillary collagen 
to fill the place of dead myocytes. Ultimately, the disruption of mechanical power by the dam-
aged myocytes becomes detrimental, and the left ventricular wall becomes thinner and dilated.
1.2. Neuroendocrine changes
The pathophysiology of LHF is characterized by hemodynamic abnormalities resulting in auto-
nomic nervous system imbalance and neurohormonal activation. Alterations in receptor activation 
cause an autonomic imbalance with increased sympathetic activity and diminished vagal activ-
ity, both of which may have profound effects on cardiac function and structure. Neurohormonal 
alterations act as a complex and combined compensatory mechanism to support and maintain 
tissue perfusion during the HFS (Table 3). However, these neurohormonal responses become 
maladaptive due to uncontrollable activation and promote progression of heart failure. The main 
sympathetic neurohormones are norepinephrine (noradrenaline) and angiotensin II, which act in 
an autocrine (myocardial synthesis) and paracrine (endocrine synthesis) manner.
1.2.1. Autonomic nervous system
Sympathetic (adrenergic) and parasympathetic (cholinergic) nerve systems are controlled by 
the central nervous system and are in balance in healthy individuals, where sympathetic acti-
vation is lower at rest, as well as in the normal heart [6]. Baroreceptors at the aortic arch and 
carotid sinuses, as well as mechanoreceptors at the cardiopulmonary tract, sense arterial wall 
tension and produce afferent signals resulting in a significant increase of excitatory (sympa-
thetic) impulses via norepinephrine or inhibitory (parasympathetic) impulses via acetylcho-
line (Figure 4). Chemoreceptors at the peripheral vessels and metaboreceptors in the muscles 
sense acid-base balance and oxygenation of the blood and produce afferent signals resulting 
in a significant increase of sympathetic stimulation (the excitatory impulse). Mechanical and 
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chemical changes like hypoxia, hypotension, or acid-base imbalance are sensed by recep-
tors, creating a feedback cascade to maintain cardiovascular homeostasis. In the case of heart 
 failure, the first response of sympathetic nervous system activation is the increasing release 
and decreasing uptake of norepinephrine at the adrenergic nerve endings. In response, the 
parasympathetic receptor activity becomes dysfunctional by the increased sympathetic stim-
ulation, which in turn leads to increasing systemic vascular resistance and heart rate.
(1) Sympathetic nervous system
(2) Renin-angiotensin system
(3) Neurohormonal alterations of renal function
 (a) Arginine vasopressin
 (b) Natriuretic peptides
(4) Neurohormonal alterations in the peripheral vasculature
 (a) Vasoconstrictors
  (i) Endothelin
  (ii) Neuropeptide Y
  (iii) Urotensin II
  (iv) Thromboxane A
2
 (b) Vasodilators
  (i) Nitric oxide
  (ii) Bradykinin
  (iii) Adrenomedullin
  (iv) Prostaglandins (PGI
2
 and PGE
2
)
  (v) Adipokines
(5) Remodeling factors
 (a) Tumor necrosis factor
 (b) Soluble ST2
 (c) Growth differentiation factor (GDF)-15
 (d) Gelectin-3
(6) Interleukin activation
(7) Anabolic metabolism dysfunctions
 (a) Insulin resistance
 (b) Growth hormone resistance
 (c) Anabolic steroid resistance
Table 3. Neuroendocrine responses.
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In the HFS, sympathetic stimulation affects several key organs to maintain cardiac output, espe-
cially the heart, the kidney, and the peripheral vasculature. Increased sympathetic activity (1) 
augments ventricular contractility and heart rate to sustain stroke volume, (2) stimulates effer-
ent arteriole vasoconstriction and proximal tubular sodium reabsorption to improve ventricu-
lar preload, and (3) leads to systemic vasoconstriction and enhanced venous tone to increase 
systemic vascular resistance and blood pressure. Alternatively, alterations in autonomic func-
tion are broadly associated with both increased cardiovascular and, in many cases, all-cause 
mortality in humans. Norepinephrine is a potent adrenergic neurotransmitter and increases 
three to four times more than the normal level in HFS. This process has opposed effects: acute 
excretion or lower level of norepinephrine is associated with improvement of cardiac function; 
however, higher levels are associated with worsening of the HFS [7]. α-Adrenergic receptors 
are present in vascular smooth muscle much more so than in cardiac myocytes; however, 
only α1-subtype receptors demonstrate significant density in myocardium, and their num-
bers increase modestly in heart failure, which leads to myocyte hypertrophy. Stimulation of 
these receptors in cardiac myocytes by norepinephrine induces myocyte growth and hyper-
trophy and reproduces fetal isoforms of contractile proteins. β-Adrenergic receptors consist of 
β1 subtype and are present in more than 80% in the heart. This system plays a critical role in 
modulating cardiac performance, specifically inotropy, chronotropy, and lusitropy. However, 
chronically elevated stimulation of the sympathetic system has detrimental repercussions 
in HFS (cardiac β-adrenergic desensitization). Ongoing adrenergic stimulation reduces the 
β-adrenergic receptor, particularly β1 concentrations in the myocardium (downregulation). 
This causes an increased expression of β-adrenergic receptor kinase inhibiting β-receptor 
(both β1 and β2) activation by phosphorylating them (functional desensitization).
Figure 4. Autonomic nervous system function.
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1.2.2. Renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system is a secondary compensatory mechanism that main-
tains intravascular volume and vascular resistance. This system is activated later in heart failure 
due to renal hypoperfusion, decreased sodium in the macula densa of the distal tubule, increased 
sympathetic stimulations (β1 adrenergic activity), and diuretic therapy. The system is very 
 sensitive and is activated with the extrication of renin from the juxtaglomerular apparatus. Renin 
is responsible for the conversion of angiotensinogen to angiotensin I (inactive decapeptide), and 
angiotensin I is then converted to angiotensin II (active octapeptide) by angiotensin-converting 
enzyme. The majority of angiotensin-converting enzyme (>90%) is found in tissues, with the rest 
located in the circulation. The activity of angiotensin-converting enzyme increases during heart 
failure with increased expression of myocardial form. Two opposing receptors are present; renin 
receptor type 1 and renin receptor type 2. Activation of type 1 receptors leads to cell growth, 
causing the release of norepinephrine from sympathetic nerves, either directly or indirectly. This 
in turn decreases lusitropy, increases afterload by inducing the release of aldosterone from the 
adrenal cortex indirectly and contributes to the increase of intravascular volume directly by pro-
moting tubular reabsorption of sodium. Furthermore, this stimulates water intake by increasing 
thirst. The activation of type 2 receptors leads to the inhibition of cell growth, vasodilatation, and 
natriuresis. On the other hand, atrial natriuretic peptide (ANP) inhibits the release of renin.
Excessive production of angiotensin II can lead to fibrosis of several organs, especially the 
heart and kidneys, and can also induce cellular proliferation of cardiac fibroblasts and the rate 
of myocyte apoptosis. Aldosterone has similar actions with unfavorable effects of angiotensin 
II. Aldosterone provokes hypertrophy and fibrosis within the vasculature and myocardium, 
resulting in ventricular stiffness, endothelial cell and baroreceptor dysfunction, and the inhi-
bition of norepinephrine uptake.
1.2.3. Renal neuroendocrine alterations
The most adverse outcome of HFS is increased salt and water retention by the kidneys, which 
results in the worsening of heart failure. Regulation of the fluid balance of the body is pri-
marily managed by body fluid osmolality and changes in plasma volumes [8]. This is a nor-
mal pathway that is observed in non-failed hearts due to excessive intake of sodium, but it 
is a detrimental pathway in heart failure. Decreasing plasma volume or blood pressure is 
perceived as tissue hypoperfusion, which then stimulates specialized baroreceptors, and in 
turn activates several neurohormonal pathways that produce hypoperfusion of the tissues. 
Inadequate perfusion of the kidney and other organs results in adverse impulses that increase 
vasopressor response via angiotensin II, aldosterone, and norepinephrine production. This 
central response increases arginine vasopressin secretion, which regulates free water clear-
ance and plasma osmolality. All of these responses try to prevent tissue hypoperfusion. 
Additionally, they can aggravate the process of heart failure and cause cardiac remodeling. 
Treatment modalities against any kind of heart failure syndrome can cause hyponatremia, 
which occurs as either depletional or delusional [9].
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The natriuretic peptides provide the most important counterregulatory effect of the neu-
rohormonal system via increasing excretion of sodium and water. Atrial (ANP) and B-type 
(BNP) natriuretic peptides are produced primarily in response to myocardial stretch due to 
pressure or volume overload: ANP from the atrial wall and BNP from the ventricular wall. 
Both peptides are responsible for vasodilatation, natriuresis, diuresis (inhibition of renin 
and aldosterone cascade), and inhibition of vascular smooth muscle proliferation. The third 
(C-type) natriuretic peptide released from endothelial cells results in vasodilatation and 
inhibits endothelin but does not promote natriuresis. These peptides increase during heart 
failure or decompensated situations, but they can also be used to guide heart failure therapy 
[10]. Both biomarkers are influenced by other factors such as obesity, arrhythmia, anemia, 
sepsis, pulmonary embolism, etc.
1.2.4. Peripheral neuroendocrine alterations
The main goal of the body is to preserve brain and cardiac circulation throughout the HFS 
via decreasing blood flow to peripheral tissues and visceral organs. The increased sympa-
thetic adrenergic stimulation of the peripheral arteries causes arteriolar vasoconstriction for 
the maintenance of arterial pressure and vasoconstriction of the peripheral veins to increase 
venous return. Counterregulatory vasodilator responses result in vasodilatation of the periph-
eral vasculature to prevent aggressive overload of the circulatory system. Loss of the endothe-
lium-mediated vasodilatory responsiveness in HFS causes the inability of counterregulatory 
and/or control of sympathetic adrenergic activation, which subsequently exacerbates heart 
failure, cardiac remodeling, and symptoms.
1.2.5. Anabolic metabolism alterations
Insulin is the strongest anabolic stimulatory signal via activation of transcription factor 
4, which is complementary to the general amino acid control pathway. In heart failure, 
the anabolic efficiency of insulin decreases more than 50%. As a principal metabolic fea-
ture of heart failure, increased insulin resistance impairs functional capacity of the heart 
and muscles and worsens heart failure via impaired metabolic efficacy, tissue fibrosis, 
apoptosis, and lipotoxicity. Growth hormone or insulin-like growth factor 1 causes an 
anabolic signal rise; however, it cannot prevent cachexia. Anabolic steroid metabolism is 
also impaired in HFS.
Anabolic failure of the body occurring during long-standing heart failure appears with different 
clinical signs (Table 4). Skeletal muscle is the largest amino acid storage pool in the body, and 
its atrophy is the first clinical sign for cardiac cachexia (proteolysis). Adipose tissue is actively 
affected by different lipolytic signals, whereas insulin resistance blocks activation of lipogenic 
enzymes (lipolysis). Osteopenia or osteoporosis can develop in higher stages of the disease. 
This catabolic/anabolic imbalance leads to tissue wasting, weight loss, and ultimately cardiac 
cachexia (body weight loss > 6% in < 1 year), which is the worst and gravest prognosis of the 
HFS. Iron deficiency is another important metabolic dysfunction that occurs secondary to blood 
loss, malnutrition, inflammation (hepcidin dysfunction), and impaired synthesis of bioactive 
heme, and it impairs enzymatic electron transfer activities in the body with or without anemia.
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1.3. Left ventricular remodeling
Reversible or irreversible left ventricular failure (LVF) results in left ventricular remodeling 
via complex changes of cardiac myocytes and nonmyocyte components of the myocardium 
(Table 5) [11]. Treatment of reversible pathologies affecting the heart can reverse this process 
and maintain the anatomohistologic structure. Irreversible pathologies lead to progressive 
loss of myofilaments and contractile function, as well as alterations in excitation-contraction 
coupling, fatal arrhythmias, and desensitization of ß-adrenergic signaling. This type of left 
heart failure impacts the development of left ventricular hypertrophy, in that pressure over-
load or myocardial accumulation causes concentric hypertrophy with increased left ventric-
ular wall stiffness, with or without left ventricular thickening. However, volume overload 
also causes eccentric hypertrophy with dilation of the left ventricular wall, with or without 
thinning. A progressive loss of connectivity of the collagen network causes progressive left 
ventricular dilatation, but it preserves the structural integrity of the heart. A change in left 
ventricular shape from an elliptical form to a spherical form creates increasing wall stress 
and mechanical energy, which results in left ventricular dilatation and wall thinning. This 
progressive dilatation causes pull-apart pathology of the papillary muscles resulting in sig-
nificant mitral regurgitation from the inability of the valve leaflets to coapt. In addition, myo-
cardial fibrosis results in arrhythmia and/or sudden death.
The heart anatomically consists of a single, intertwined muscle band. The muscle fibers, both 
inside and out, achieve maximum contractile performance by making a 60° angle from each 
other. This angle increases when a stretching occurs, as in heart failure, and the elliptical 
shape of the heart mutates into a spherical shape, which decreases stroke work and volume 
significantly. The oblique arrays of apical fibers create 60% LVEF with 15% fractional shorten-
ing, while transverse arrays can create just 15% LVEF. When the arrays of myocardial fibers 
are unbalanced from any cause, the contractile performance of the heart will be affected 
(Table 6). The enlargement of myocardial cells alters left ventricular shape and  function. 
1. Proteolysis
2. Lipolysis
3. Osteolysis
4. Cardiac cachexia
 a. Hypoalbuminemia
 b. Anemia
 c. Impaired glucose tolerance
 d. Inflammation
 e. Anorexia
5. Iron deficiency
6. Hyperuricemia
Table 4. Clinical presentation of imbalanced catabolic status in heart failure.
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Systolic dysfunction disrupts emptying of the ventricular chamber and decreases stroke vol-
ume, whereas volume overload increases left ventricular end-diastolic pressure. Diastolic 
dysfunction reduces the filling capacity of the LV due to myocardial stiffness, despite the 
relatively preserved contractile performance and ejection fraction. Each type of cardiomy-
opathy has one or both dysfunctional processes. Dilated cardiomyopathy is characterized 
by impaired systolic function, with enlargement of cardiac chambers, whereas hypertrophic 
cardiomyopathy is depicted by a smaller ventricular cavity due to a hypertrophic myocar-
dium. Restrictive cardiomyopathy occurs secondarily from diastolic dysfunction and exhibits 
normal chamber size.
2. Right heart failure
The right ventricle (RV) is not a mirror image of the LV and has its own anatomy, circula-
tion, physiology, and hemodynamics. The RV consists of separated inlet (receives blood from 
the right atrium) and outlet (funnels blood into the pulmonary artery) portions and has a 
crescent-shaped structure with a concave free wall and convex interventricular septum (IVS) 
[12]. It is relatively thin walled with the muscle mass of the RV being relatively less than that 
(a) Myocardial infarction causes loss of contraction and subsequent to fibrosis of affected heart muscle, which 
breakdowns the array of myocardial fibers due to stretching of myocardial fibers
(b) Valvular and/or congenital heart diseases leading to biventricular volume overload derange the array of myocardial 
fibers due to ventricular dilatation
(c) Cardiomyopathies and the intrinsic disorders of the myocardium may cause a breakdown of the array of 
myocardial fibers due to both mechanisms
Table 6. Pathophysiologic changes in different etiologies.
(1) Structural alterations
 (a) Ultrastructural remodeling
 (b) Mitochondrial remodeling
 (c) Extracellular matrix remodeling
 (d) Metabolic remodeling
(2) Electrophysiologic alterations
 (a) Action potential remodeling
 (b) Excitation-contraction coupling remodeling
 (c) Repolarization remodeling
(3) ß-Adrenergic receptor signaling alterations
Table 5. Myocardial remodeling.
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of the LV (about 1/6). However, the RV can eject almost an equal stroke volume as the LV into 
a lower afterloaded (low pressure-low resistance) and highly compliant pulmonary circuit 
with a more complex contractile mechanism, but with lower stroke work than the LV (25% 
of the left ventricular stroke work). The dominant movements of the RV include longitudinal 
shortening, pressing of the free wall against the septum, contraction of the IVS, and a “wring-
ing” action of the LV (Table 7). Right heart failure (RHF) is defined as persistent signs and 
symptoms of right ventricular dysfunction (RVD) in the absence of LVF, cardiac tamponade, 
ventricular arrhythmias, and/or pneumothorax.
2.1. Pathophysiology of right heart failure
Right-sided heart failure has been accepted as an eventual consequence of left-sided heart 
failure (the LV as guilty and the RV as victim), and the RV has been largely ignored as a 
passive conduit or a bystander chamber for several decades [13]. The International Right 
Heart Foundation Working Group describes a comprehensive definition of RHF: “A clinical 
syndrome due to an alteration of structure and/or function of the right heart circulatory 
system that leads to suboptimal delivery of blood flow (high or low) to the pulmonary 
circulation and/or elevated venous pressures—at rest or with exercise” [14]. The defini-
tion of RHF represents a dysfunction of any components that constitute the right heart 
circulatory system, from systemic veins (post-systemic capillaries) to the pulmonary artery 
(pre-pulmonary capillaries). Right ventricular failure (RVF) can develop most commonly 
secondarily to left-sided HFS, but some specific etiologic pathologies result in isolated 
right-sided HFS (Table 8) [15]. The well-known etiologic reasons of RVF are pulmonary 
arterial hypertension (PAH) with or without LHF, LVF, or implantation of a left ventricular 
assist device (LVAD).
Pulmonary arterial hypertension (PAH) is seen in almost all RHF scenarios and occurs as a 
consequence of chronic left heart pathologies, chronic lung diseases, pulmonary embolism, 
or any pathology affecting the distal pulmonary vascular bed. Pressure overload caused by 
pre- or post-capillary dynamics starts the “RVD and RVF” vicious circle (Figure 5). The hemo-
dynamic definition of PAH type is critical to determine the appropriate treatment modality. 
Pulmonary hypertension is a common complication of LHF and the diagnosis of PAH-related 
hemodynamic parameters (Table 9). The main differentiation between pre- and post-pulmo-
nary types is pressure gradients between both sides of the pulmonary capillaries, whereas 
the diastolic pressure gradient has more prognostic value due to lesser dependence of stroke 
1. Longitudinal/twisting motion (septal contraction) 80%
Interventricular septum shares fibers with both ventricles
LV maintains 20–40% RV contractile function
2. Transverse motion (free wall contraction) 20%
3. Traction of the RV free wall at the points of binding to the LV
Table 7. Right ventricular contractile functions.
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volume and loading conditions [16]. The threshold level of the transpulmonary pressure gra-
dient (TPG) to discriminate between pre- and post-capillary PHT should be 12 mmHg. The 
diastolic pulmonary gradient (<5 mmHg) combined with the systemic blood pressure and 
cardiac output is superior to the TPG for determining the differential diagnosis between pul-
monary vascular disease, high output or high left heart filling state, and sepsis.
Right ventricular failure has a specific pathophysiologic algorithm (Figure 6). Increased after-
load due to pressure overload of the pulmonary circulation prolongs the systolic contraction 
of the RV. On the other hand, the RV is able to tolerate an increased preload due to volume 
overload. In the early phase of RVF, wall thickening and enhanced contractility are the first 
important responses of pressure overload, which creates an adaptive remodeling with con-
centric hypertrophy and preserved right ventricular function. In chronic, higher afterload 
states even though myocardial contractility is advanced, the right pump functions decrease 
proportionally, and contractile dysfunction occurs later in the process. This remodeling pro-
cess is sustained by the contribution of neurohormonal, genetic, and molecular components. 
Meanwhile, the RV dilates to provide adequate stroke volume, but this counter effect leads 
to tricuspid annular dilatation, valve coaptation defect, and eventually significant tricus-
pid regurgitation. This process triggers a maladaptive remodeling, which causes eccentric 
hypertrophy and deteriorated right ventricular function. In the beginning of diastole of the 
LV, the RV is contracting, and the IVS moves leftward causing ventricular dyssynchrony. 
Ventricular dyssynchrony accelerates right heart and biventricular failure with several fatal 
complications such as arrhythmia, hepatorenal failure, protein-losing enteropathy, and car-
diac cachexia. Myocardial ischemia or infarction of the RV is not a significant factor for heart 
1. Pressure overload
 a. Left-sided HFS (most common cause)
 b. Primary pulmonary hypertension
 c. Pulmonary embolism
 d. RVOT obstruction and/or peripheral pulmonary stenosis
2. Volume overload
 a. Tricuspid regurgitation
 b. Pulmonary regurgitation
 c. Atrial septal defect and/or anomalous pulmonary venous return
 d. Coronary artery fistula into right chambers
 e. Carcinoid syndrome
3. Ischemia and infarction
4. Intrinsic myocardial process
5. Arrhythmogenic RV dysplasia
6. Chronic lung diseases
Table 8. Etiology of right heart failure.
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failure as it is in LVF, because the right ventricular free wall is supplied by a single coronary 
artery, whereas the IVS and the rest of the RV have the benefit of left-sided collateral blood 
flow, which protects the RV against ischemia.
2.2. Transition of left heart failure to right heart failure
The main cause of RHF is PAH related to an intolerable afterload increase in pulmonary circu-
lation due to LHF and is associated with elevated left ventricular filling pressure, severe mitral 
regurgitation, and impaired left atrial compliance secondary to a dilated LV. Therefore, LHF 
is the most common (65–80%) reason for PAH (group 2 PAH) [17]. Sudden elevation of the 
left heart and consequently pulmonary circulatory pressure increases endothelial permeability 
causing fluid infiltration into alveolar and interstitial spaces. Pulmonary edema is one of the 
first signs of acute left HFS, although decreased permeability in the chronic stage of LHF does 
not cause pulmonary congestion. Significant overloading of the pulmonary arterial vascula-
ture leads to mechanical, neurohormonal, and molecular changes in the pulmonary vascula-
ture system. Destructive neurohormonal changes cause the desensitization of the pulmonary 
vascular bed against vasodilator agents (nitric oxide, natriuretic peptides, etc.) and excretion of 
Figure 5. Pathophysiological changes caused by pulmonary hypertension on the right heart.
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vasoconstrictor agents (endothelin-1, etc.). Vasoconstriction is the net response of the pulmo-
nary vasculature system to sustain and maintain the right heart stroke volume. If this process 
cannot be treated or resolved, long-standing PAH will cause reactive structural changes and 
interstitial fibrosis in the pulmonary vasculature, specifically in the small pulmonary resis-
tance arteries, and will result in increasing pulmonary vascular resistance (PVR) [18]. The next 
step of this maladaptive process is pulmonary arteriolar remodeling, which includes thicken-
ing of the alveolar-capillary membrane, medial hypertrophy, intimal and adventitial fibrosis, 
and luminal occlusion in small pulmonary arterioles. Arterial resistance and compliance in 
the lung are determined by the small pulmonary resistance vessels, in contrast to the systemic 
circulation determined by the aorta. The last stage after irreversible PVR is remodeling of the 
right heart and organs behind the RV. Maladaptive remodeling of the RV is similar to that of 
the LV in that there is an increase in myocardial fibrosis, dilatation, wall thinning, tricuspid 
insufficiency, and contractile failure (Figure 6) [19]. Pulmonary hypertension associated with 
left heart disease is a significant predictor for rehospitalization and mortality [20].
Increased filling pressure of the right heart chambers reflects back to the systemic venous sys-
tem and affects visceral and peripheral tissues. The left HFS with low systemic perfusion pres-
sure and elevated PVR contributes to this process and aggravates organ dysfunction. The liver 
is the most affected organ in RHF via congestive hepatopathy. Cardiac hepatopathy is a clini-
cal entity with signs and symptoms of elevated hepatic biomarkers approximately twice the 
upper limit of normal: aspartate aminotransferase > 100 U/L, alkaline phosphatase > 200 U/L, 
and serum bilirubin > 2 mg/dL [21]. Increased elevation of the right atrial pressure and/or 
severe tricuspid regurgitation implies increased hepatic venous pressure causing hepatic 
circulatory failure, hepatic congestion, and hepatic ischemia. In the early phase, sinusoidal 
congestion with hemorrhagic necrosis and hepatocyte degeneration dominates the revers-
ible silent clinical status. Chronically elevated right heart pressures disrupt hepatic venous 
return and consequently hepatic arterial circulation, so that decreased hepatic oxygen and 
LVEF RVEF CVP (RAP) mPAP PCWP  
(LVEDP)
TPG DPG PVR
Normal Normal Normal <10 mmHg <15 mmHg <10 mmHg <10 mmHg <5 mmHg <2 WU
Precapillary  
(PVD)
Normal Decreased >15 mmHg ≥25 mmHg ≤15 mmHg >12 mmHg >7 mmHg >3 WU
Post-capillary  
(LHF)
Decreased Normal >15 mmHg ≥25 mmHg >15 mmHg ≤12 mmHg <7 mmHg <3 WU
Combined Decreased Decreased >15 mmHg ≥25 mmHg >15 mmHg >12 mmHg >7 mmHg >3 WU
Irreversible  
PAH
Decreased Decreased >15 mmHg ≥25 mmHg >15 mmHg >15 mmHg >10 mmHg >6 WU
CVP, central venous pressure; DPG, diastolic pulmonary gradient; LHF, left heart failure; LVEDP, left ventricular 
end-diastolic pressure; LVEF, left ventricular ejection fraction; PAH, pulmonary arterial hypertension; mPAP, mean 
pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVD, pulmonary vascular disease; 
PVR, pulmonary vascular resistance; Rap, right atrial pressure; RVEF, right ventricular ejection fraction; TPG, trans-
pulmonary gradient.
Table 9. Pulmonary hypertension types.
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nutrient delivery results in hepatocellular necrosis, fatty changes, and fibrosis. The congested 
and hypoxic liver cannot work properly, and, ultimately, cardiac cirrhosis develops, which is 
characterized by hepatic insufficiency such as portal hypertension, coagulation abnormality, 
biliary malfunctions, and other metabolic dysfunctions.
3. Right ventricular failure after left ventricular assist device 
implantation
End-stage HFS requires mechanical uni- or biventricular circulatory support, but isolated 
LVAD implantation covers the majority (>90%) of treatments. Uni- or biventricular failure 
can be treated only by LVAD implantation. This therapy has several indications (Table 10). 
Currently, more LVADs have been implanted as destination therapy in advanced LVF with 
both advantages and disadvantages. The main intention of LVAD therapy is to provide support 
to the failing LV, allowing for improved stroke volume that ultimately promotes peripheral 
tissue perfusion. Furthermore, the LVAD improves right ventricular function due to unload-
ing of the LV and consequently the RV [22]. The most serious complication of LVAD therapy 
can be a newly developed or continued deterioration of RVF as pathophysiologic sequela, 
which worsens postoperative mortality and morbidity, end-organ dysfunction due to severe 
congestion (coagulopathy, malnutrition, renal and hepatic dysfunctions, edema, ascites, etc.), 
Figure 6. RVF pathophysiology. IVS, interventricular septum; LVF, left ventricular failure; RCA, right coronary 
artery; RV, right ventricle; RVD, right ventricular dysfunction; RVF, right ventricular failure; RVH, right ventricular 
hypertrophy; TR, tricuspid regurgitation.
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 hospitalization durations, and success of bridge to transplant therapy. The classification of RVF 
after LVAD implantation is described by The Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) and is associated with increased perioperative mortality, 
prolonged length of stay, and worse survival even after cardiac transplantation (Table 11) 
[23]. The definition of serious RVF after LVAD implantation must be very clear, because it 
needs to be treated by heart transplantation or mechanical circulatory support (Table 12) 
[24]. Post-implant RVF can occur beyond the immediate postoperative period or later, and it 
significantly impacts survival after LVAD implantation because it is a progressive condition. 
Early post-implant RVF results in worse survival and is predicted by greater preoperative 
tricuspid incompetence [25]. Prolonged RVF for more than 2 weeks is associated with adverse 
outcomes, with the incidence of moderate or severe RVF necessitating right or biventricular 
ventricular assist device placement after LVAD implantation ranging between 10 and 40% [26].
Right ventricular output determinants such as preload, afterload, and contractility are 
deranged in RVF after LVAD implantation (Table 13). Post-implant RVF is multifactorial and 
includes leftward shifting of the IVS, suboptimal RV afterload reduction, and RV myocardial 
dysfunction. Echocardiography is the primary imaging modality for monitoring cardiac func-
tion, filling and contraction behaviors, and device malfunctions [27].
1. Mild
 a. Post-implant inotropes, inhaled nitric oxide, or intravenous vasodilators not continued beyond post-op Day 7 after 
LVAD implant
2. Moderate
 a. Post-implant inotropes, inhaled nitric oxide, or intravenous vasodilators continued beyond post-op Day 7 and up 
to post-op Day 14 after LVAD implant
 b. CVP or right atrial pressure >16 mm Hg
3. Severe
 a. Prolonged post-implant inotropes, inhaled nitric oxide, or intravenous vasodilators continued beyond post-op 
Day 14 after LVAD implant
 b. CVP or right atrial pressure >16 mmHg
 c. Need for RVAD at any time after LVAD implant
CVP, central venous pressure; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; 
LVAD, left ventricular assist device; RVAD, right ventricular assist device; RVF, right ventricular failure.
Table 11. INTERMACS definition of post-implant RVF (severity scale).
1. Bridge to transplantation (BTT)
2. Bridge to candidacy for transplantation (BTC)
3. Destination therapy (DT)
4. Bridge to recovery (BTR)
Table 10. LVAD indications.
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Increased preload (volume overload) causes the RV to fail due to the overstretching of the 
right ventricular myocardium. Improved left-sided forward flow with mechanical unload-
ing in conjunction with perioperative transfusions of blood products suggests that increased 
venous return to the RV can be well tolerated. However, excessive fluid transfusions can 
aggravate RVF due to the effect of the Frank-Starling mechanism, exacerbation of tricuspid 
regurgitation, reduction of septal contribution, and ventriculo-arterial uncoupling. The main 
echocardiographic findings are a leftward shift of the interatrial septum, distension of the RV, 
worsening of tricuspid regurgitation, and plethora.
Despite the benefit of the LVAD decompressing the LV and reducing pulmonary overload sig-
nificantly, it is not successful in every situation due to irreversibility of PAH, which is the main 
determinant for irreducible afterload. Reverse remodeling of the pulmonary vasculature can 
1. Need for intravenous inotrope and pulmonary vasodilator therapy > 14 days
2. Need for RVAD implantation
3. Hemodynamic parameters
 a. CVP > 16 mmHg
 b. CVP/PCWP > 2/3
 c. PVR > 2 Wood units
 d. MAP < 55 mmHg
 e. CI < 2 L/min/m2
 f. Inotropic support > 20 U
 g. MVS < 55%
 h. HR > 100 / min
4. Laboratory parameters
 a. Bilirubin > 2 mg/dL
 b. Creatinine > 2 mg/dL
 c. AST > 80 IU/L
 d. Albumin < 3 g/dL
5. Echocardiographic parameters
 a. TAPSE < 7.5 mm
 b. RAD > 5 cm
 c. RVEDD > 3.5 cm
 d. RVEF < 30%
AST, aspartate aminotransferase; CI, cardiac index; CVP, central venous pressure; HR, heart rate; MAP, mean arterial 
pressure; MVS, mixed venous oxygen saturation; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary 
vascular resistance; RAD, right atrial diameter; RVAD, right ventricular assist device; RVEDD, right ventricular end-
diastolic diameter; RVEF, right ventricular ejection fraction; RVF, right ventricular failure; TAPSE, tricuspid annular 
plane systolic excursion.
Table 12. Definition of serious RVF.
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potentially occur with continued unloading, and, unlike heart transplantation, elevated PVR 
is not able to predict post-implant RVF. The second reason is continuity of preoperative signif-
icant mitral regurgitation due to untouched strategy, which cannot be improved and results 
pulmonary congestion though implantation of LVAD postoperatively. Because the RV has a 
very different myocardial structure than the left side and is very sensitive to acute change in 
afterload, any limited or huge failure of afterload decreasing causes significant post-implant 
RVF due to ineffectiveness of Frank-Starling mechanism on the right heart.
Improvement of right ventricular contractility after LVAD implantation is a predictor for 
positive outcomes; however, if the right ventricular systolic function does not improve, there 
are several risk-scoring algorithms that can be used to help predict the need for biventricu-
lar support [28]. Excessive leftward shift of the IVS due to volume overload and/or aggres-
sive LV decompression may decrease septal contribution to right ventricular contraction 
causing mechanical dyssynchrony and elevation of right ventricular work. The main echo-
cardiographic findings of post-implant RVF are decreased tricuspid annular plane systolic 
excursion (TAPSE < 7.5 mm), reduced right ventricular fractional area change (RVFAC < 35%), 
increased RV/LV ratio (>0.75), and septal akinesia. Severe unloading of the LV affects left ven-
tricular contraction, depending on it right ventricular systolic function. In normal heart, the 
left ventricular contraction supplies roughly one half and septal contraction one quarter of the 
right ventricular ejection function. Prevention and treatment of RVF can be provided with the 
maintenance of the ejection function of the LV.
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1. Preload
 a. Increased left ventricular output and venous return (approximately 100%)
 b. Excessive administration of blood products and fluids
2. Afterload
 a. Maintenance of pulmonary arterial hypertension
 b. Respiratory problems
3. Contractility
 a. Overstretched cardiac myofibrils (decreasing stroke volume)
 b. Aggravated annular dilatation and tricuspid regurgitation
 c. Impaired ventricular interdependence (left ventricular failure)
 d. Dyssynchronism of interventricular septum (noncontractible and/or leftward shift of the septum)
Table 13. Determinants leading to RVF after LVAD.
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